CA2362930C - Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation - Google Patents
Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation Download PDFInfo
- Publication number
- CA2362930C CA2362930C CA2362930A CA2362930A CA2362930C CA 2362930 C CA2362930 C CA 2362930C CA 2362930 A CA2362930 A CA 2362930A CA 2362930 A CA2362930 A CA 2362930A CA 2362930 C CA2362930 C CA 2362930C
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- acid
- nitric oxide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention a pour objet de nouveaux composés nitrosés et/ou nitrosylés inhibiteurs de la pompe à protons, et de nouvelles compositions comportant au moins un composé inhibiteur de la pompe à protons, éventuellement substitué par au moins un groupe NO et/ou NO2, et éventuellement au moins un composé qui donne, transfère ou émet de l'oxyde nitrique, stimule la synthèse endogène de l'oxyde nitrique, élève les niveaux endogènes de facteur de relaxation dérivé de l'endothélium ou constitue un substrat pour la synthase de l'oxyde nitrique, et/ou au moins un médicament anti-inflammatoire non stéroïdien, un antiacide sélectif inhibiteur de COX-2, un réactif contenant du bismuth, un composé antibactérien dégradable à l'acide et des mélanges de ceux-ci. La présente invention a également pour objet des méthodes pour traiter et/ou prévenir les troubles gastro-intestinaux; faciliter la cicatrisation des ulcères; réduire la récurrence des ulcères; améliorer les propriétés de protection gastrique, les propriétés anti-helicobacter pylori ou les propriétés antiacides des inhibiteurs de la pompe à protons; diminuer ou supprimer la toxicité gastro-intestinale associée à l'utilisation de composés anti-inflammatoires non stéroïdiens; traiter les infections à helicobacter pylori et les infections virales. Les composés et/ou les compositions de la présente invention peuvent également se présenter sous la forme d'une trousse pharmaceutique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12211199P | 1999-02-26 | 1999-02-26 | |
US60/122,111 | 1999-02-26 | ||
PCT/US2000/002524 WO2000050037A1 (fr) | 1999-02-26 | 2000-02-25 | Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2362930A1 CA2362930A1 (fr) | 2000-08-31 |
CA2362930C true CA2362930C (fr) | 2010-10-05 |
Family
ID=22400684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2362930A Expired - Fee Related CA2362930C (fr) | 1999-02-26 | 2000-02-25 | Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1154771A4 (fr) |
JP (1) | JP2002537336A (fr) |
AU (2) | AU781133B2 (fr) |
CA (1) | CA2362930C (fr) |
WO (1) | WO2000050037A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002476D0 (sv) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
US20050020637A1 (en) * | 2001-11-19 | 2005-01-27 | Wolfgang-Alexander Simon | Agents for the treatment of airway disorders |
TW200403072A (en) * | 2002-01-23 | 2004-03-01 | Upjohn Co | Combination therapy for the treatment of bacterial infections |
PL370839A1 (en) * | 2002-03-14 | 2005-05-30 | Altana Pharma Ag | Use of proton pump inhibitors for the treatment of airway disorders |
WO2003082854A1 (fr) * | 2002-03-29 | 2003-10-09 | Zeria Pharmaceutical Co., Ltd. | Derives 1-n-aminobenzimidazole |
AU2003223491A1 (en) * | 2002-04-05 | 2003-10-27 | Nitromed, Inc. | Nitric oxide donors, compositions and methods of use |
US7211590B2 (en) | 2002-08-01 | 2007-05-01 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
FR2845915B1 (fr) * | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
FR2845917B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
JP2007522217A (ja) * | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
TW200606163A (en) | 2004-04-22 | 2006-02-16 | Eisai Co Ltd | Imidazopyridine compound |
US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
US20090018091A1 (en) | 2005-08-02 | 2009-01-15 | Nitromed, Inc. | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use |
JP5075254B2 (ja) | 2011-01-07 | 2012-11-21 | スノーデン株式会社 | 胃酸及びガストリンの産生を抑制する乳酸菌 |
CN115645396A (zh) * | 2020-02-26 | 2023-01-31 | 上海科技大学 | 丙基-2-咪唑二硫醚在抗冠状病毒中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117268A (ja) * | 1991-10-22 | 1993-05-14 | Yoshitomi Pharmaceut Ind Ltd | ピリジン化合物 |
IL105155A (en) * | 1992-04-24 | 1999-05-09 | Astra Ab | Synergistic combination of an inhibitor of gastric acid secretion with an acid-breaking antibiotic |
SG49853A1 (en) * | 1993-08-16 | 2001-07-24 | Novartis Ag | Novel macrolides and the use thereof |
CA2192202A1 (fr) * | 1994-06-10 | 1995-12-21 | Bernhard Kohl | Arylalkylthioalkylthiopyridines substituees utilisees pour lutter contre des bacteries helicobacter |
NZ288608A (en) * | 1994-06-10 | 1999-01-28 | Byk Gulden Lomberg Chem Fab | Substituted pyridinylmethyl-thio(or sulphinyl)-benzimidazole(or 1h-imidazo-[2,3-b]-pyridine) and medicaments to combat heliobacter bacteria |
DE4420523A1 (de) * | 1994-06-13 | 1995-12-14 | Cassella Ag | Verwendung von NO-freisetzenden Verbindungen zur Behandlung und Vorbeugung von systemischen Entzündungssyndromen |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
CN1238694A (zh) * | 1996-11-22 | 1999-12-15 | 普罗克特和甘保尔公司 | 治疗肠胃病用的含铋和nsaid的组合物 |
EP0946559A2 (fr) * | 1996-12-20 | 1999-10-06 | Byk Gulden Lomberg Chemische Fabrik GmbH | Imidazopyridazines |
AU6551198A (en) * | 1997-05-30 | 1998-12-30 | Dr. Reddy's Research Foundation | Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them |
-
2000
- 2000-02-25 AU AU32196/00A patent/AU781133B2/en not_active Ceased
- 2000-02-25 WO PCT/US2000/002524 patent/WO2000050037A1/fr active IP Right Grant
- 2000-02-25 EP EP00910039A patent/EP1154771A4/fr not_active Withdrawn
- 2000-02-25 CA CA2362930A patent/CA2362930C/fr not_active Expired - Fee Related
- 2000-02-25 JP JP2000600648A patent/JP2002537336A/ja active Pending
-
2005
- 2005-06-10 AU AU2005202553A patent/AU2005202553A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2005202553A1 (en) | 2005-07-07 |
JP2002537336A (ja) | 2002-11-05 |
AU781133B2 (en) | 2005-05-05 |
CA2362930A1 (fr) | 2000-08-31 |
EP1154771A4 (fr) | 2005-04-20 |
AU3219600A (en) | 2000-09-14 |
EP1154771A1 (fr) | 2001-11-21 |
WO2000050037A1 (fr) | 2000-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005202553A1 (en) | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | |
US20070179150A1 (en) | Nitrosated proton pump inhibitors, compositions and methods of use | |
US7129251B2 (en) | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | |
US7332505B2 (en) | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | |
US6693122B2 (en) | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | |
US6727364B2 (en) | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | |
KR20110061573A (ko) | Nadph 옥시다아제 억제제로서 피라졸로 피리딘 유도체 | |
AU5701699A (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | |
JP2005538110A (ja) | シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法 | |
EP0330329B1 (fr) | Dérivés de pyrimidine anti-ulcères | |
AU2004202027B2 (en) | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | |
JPH1036367A (ja) | ピリジン化合物 | |
JPH1036368A (ja) | ピリジン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |